Incidence of diabetes in NOD or SR-A^−/− NOD mice treated with poly(I∶C).

(A) We followed diabetes onset in SR-A−/− NOD mice or NOD given high-dose poly(I∶C) (300 µg/mouse) for 28 days from 3–4 weeks of age at 20 weeks of age. Diabetes progression was significantly accelerated in SR-A−/− NOD mice treated with poly(I∶C) compared with untreated SR-A−/− NOD mice (* p value = 0.0133 by log-rank test). (B) We followed diabetes onset in SR-A−/− NOD or NOD mice given low-dose poly(I∶C) (100 µg/mouse) or high-dose poly(I∶C) (300 µg/mouse) for 28 days from 3–4 weeks of age to 40 weeks of age. Diabetes progression was significantly suppressed by low-dose poly(I∶C) in NOD mice compared with untreated NOD mice (* p value = 0.0470 by log rank test). Diabetes progression in SR-A−/− NOD mice treated with low-dose poly(I∶C) was significantly accelerated compared with that in NOD mice treated with low-dose poly(I∶C) (* p value = 0.0385 by log rank test). High-dose poly(I∶C) treatment could not suppress diabetes progression in SR-A−/− NOD or NOD mice compared with untreated NOD mice. Diabetes progression was suppressed only by low-dose poly(I∶C) treatment in NOD mice.